|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
Open Label Phase I Clinical Trial of Crotoxin in Patients With Advanced Cancer Using an Intravenous Route of Administration
The primary objective of the study is to assess whether human subjects can be made tolerant to intravenously administered Crotoxin and achieve higher and more therapeutically effective doses levels without the previously reported adverse effects associated with bolus i.m. administration.
100 项与 Celtic Biotech Ltd. 相关的临床结果
0 项与 Celtic Biotech Ltd. 相关的专利(医药)
100 项与 Celtic Biotech Ltd. 相关的药物交易
100 项与 Celtic Biotech Ltd. 相关的转化医学